April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Real-World Vision Outcomes in RVO Treated With Anti-VEGF Injections- An Analysis of EMR Data From a Large Health System
Author Affiliations & Notes
  • Hitesh Chandwani
    GHOSR, Allergan, Inc., Irvine, CA
  • Ashley L Cole
    CHDA, Allergan, Inc., Irvine, CA
  • Joanna Campbell
    GHOSR, Allergan, Inc., Irvine, CA
  • Herbert Ingraham
    Opthalmology, Geisinger Health System, Danville, PA
  • Arghavan Almony
    Ophthalmology, Carolina Eye Associates, Southern Pines, NC
  • Szilard Kiss
    Ophthalmology, Weill Cornell Medical College, New York, NY
  • Steven Marks
    Opthalmology, Geisinger Health System, Danville, PA
  • Jonathan W Kowalski
    GHOSR, Allergan, Inc., Irvine, CA
  • Nancy M Holekamp
    The Pepose Vision Institute, Chesterfield, MO
    Ophthalmology, Washington University School of Medicine, St. Louis, MO
  • Footnotes
    Commercial Relationships Hitesh Chandwani, Allergan, Inc. (E); Ashley Cole, Allergan, Inc. (E); Joanna Campbell, Allergan, Inc. (E); Herbert Ingraham, Geisinger Health System (E); Arghavan Almony, Allergan, Inc. (C); Szilard Kiss, Alimera (C), Alimera (R), Allergan, Inc. (C), Allergan, Inc. (F), Allergan, Inc. (R), Genentech (C), Genentech (F), Genentech (R), Regeneron (C), Regeneron (F), Regeneron (R); Steven Marks, Geisinger Health System (E); Jonathan Kowalski, Allergan, Inc. (E); Nancy Holekamp, Allergan, Inc. (C), Allergan, Inc. (R), Genentech (C), Genentech (R), Regeneron (C), Regeneron (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3919. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Hitesh Chandwani, Ashley L Cole, Joanna Campbell, Herbert Ingraham, Arghavan Almony, Szilard Kiss, Steven Marks, Jonathan W Kowalski, Nancy M Holekamp; Real-World Vision Outcomes in RVO Treated With Anti-VEGF Injections- An Analysis of EMR Data From a Large Health System. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3919.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Prior studies have demonstrated less frequent anti-vascular endothelial growth factor (anti-VEGF) utilization in retinal diseases in clinical practice compared with landmark randomized controlled trials (RCTs). The purpose of this study is to further examine vision outcomes in retinal vein occlusion (RVO) patients managed with intravitreal anti-VEGF therapy in clinical practice.


This is a retrospective analysis of electronic medical records from an integrated health system in the United States. The sample included eyes of RVO patients receiving initial treatment with intravitreal ranibizumab or bevacizumab from Jan 2007 to Feb 2013, with corrected visual acuity (CVA) from 20/40 - 20/400 at index treatment (baseline), and at least 3 months follow-up. Data missing due to missing visit, or invalid or missing CVA, were imputed using the last observation carried forward (LOCF) approach. Snellen visual acuities were converted to the ETDRS scale using a published algorithm. The number of anti-VEGF injections, change in CVA from baseline, and proportion of eyes improving ≥3 lines were assessed at 3, 6, and 12 months from the index anti-VEGF treatment. Analyses were performed on observed data and data imputed by LOCF.


Seventy-seven eyes met all inclusion criteria with mean (SD) CVA at baseline of 51.7 (15.4) letters. Of the 77 eyes, 71 and 63 eyes had follow-up through 6 and 12 months, respectively. At 3, 6 and 12 months: the mean numbers of anti-VEGF injections were 2.2, 3.0, and 4.5; mean CVA change from baseline was 11.4, 7.9, and 6.2 letters, using LOCF; and proportions of eyes gaining ≥3 lines were 41.6%, 35.2%, and 31.8% (Table 1).


In this large health care system retrospective analysis, frequency of intravitreal injections and subsequent visual acuity improvement in clinical practice are lower than that reported in landmark RCTs. Earlier studies demonstrating less frequent anti-VEGF injections than in RCTs hypothesized that less frequent injections might result in less visual acuity improvement than seen in RCTs. This study links less frequent utilization of anti-VEGF injections in RVO to less visual acuity improvement. Additional research is needed to assess the factors that may affect utilization of anti-VEGF injections and other patient characteristics differing from RCTs that may affect vision outcomes.

Table 1.Vision Outcomes at Follow-Up
Table 1.Vision Outcomes at Follow-Up
Keywords: 749 vascular occlusion/vascular occlusive disease • 462 clinical (human) or epidemiologic studies: outcomes/complications • 754 visual acuity  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.